Showing 1001-1010 of 5806 results for "".
Part 2, 1726 nm lasers: All about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24340/Chapter 2 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods.Journal Club: Dupilumab and Atopic March
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-dupilumab-and-atopic-march/32405/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Peter Lio, MD, discuss recent research indicating a reduced risk of atopic march in pediatric atopic dermatitis patients on dupilumab.Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. ReducedHS Tips and Lizards
https://practicaldermatology.com/series/the-practical-dermatology-podcast/hs-tips-and-lizards/35858/The latest news and updates, plus a psoriasis update from Jashin J. Wu, MD, FAAD, at Music City SCALE, and Jennifer L. Hsiao, MD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss treating hidradenitis suppurativa and play a game of "Two Truths and a Lie."A New Year and New Beginnings
https://practicaldermatology.com/series/the-practical-dermatology-podcast/a-new-year-and-new-beginnings/32417/The Practical Dermatology Podcast relaunches with the latest news to start 2025 and a conversation between Chief Medical Editor Neal Bhatia, MD, FAAD, and new Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD. Dr. Bhatia and Dr. Swanson discuss the new wave of atopic dermatitis therapeuticExperts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvPractically Here
https://practicaldermatology.com/series/the-practical-dermatology-podcast/practically-here/18186/Discover the Practical Dermatology podcast, taking you into the world of dermatology care with in-depth conversations with physicians, medical aesthetics industry, and other healthcare experts.The Importance of Keeping Up with New Developments
https://practicaldermatology.com/conferences/maui-derm-2024/the-importance-of-keeping-up-with-new-developments/20257/Practical Dermatology® Chief Medical Editor Neal Bhatia, MD, chats with Resident Of Distinction Award-winner Dawn Queen, MD, at Maui Derm 2024, about the critical role of continuing to educate yourself as a practitioner, and the importance of keeping on top of new drugs and therapies in daily practiHow Combination Treatments Can Address Unmet Needs
https://practicaldermatology.com/conferences/maui-derm-2024/how-combination-treatments-can-address-unmet-needs/20243/Suneel Chilukuri, MD, talks with Chief Medical Editor Neal Bhatia, MD, about the progress cosmetic dermatology has made to fill previous gaps in options to address areas such as the chest, neck, and knees, especially with the range of advanced devices that often produce even better results when usedHow to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.DermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)